Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat

Bone

Volumn 38, Issue 1, 2006, Pages 74-84

  Lazarenko, Oxana P ^a   Rzonca, Sylwia O ^a   Suva, Larry J ^b   Lecka Czernik, Beata ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone; Fat; MCC 555; Netoglitazone; PPAR gamma

Indexed keywords

ANTIDIABETIC AGENT; COLLAGEN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 4; NETOGLITAZONE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MARROW; BONE MARROW CULTURE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINE; CELL TYPE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; HYPOGLYCEMIA; IN VITRO STUDY; LIPID STORAGE; MALE; MARKER GENE; MESENCHYME CELL; MOUSE; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOLYSIS; QUALITY CONTROL; TRABECULAR BONE; WEIGHT;

ADIPOCYTES; ANIMALS; BONE DENSITY; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENETIC MARKERS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 29344470714     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.07.008     Document Type: Article

References (42)

1. M. Stumvoll, and H.U. Haring Glitazones: clinical effects and molecular mechanisms Ann. Med. 34 2002 217 224
2. A.L. Werner, and M.T. Travaglini A review of rosiglitazone in type 2 diabetes mellitus Pharmacotherapy 21 2001 1082 1099
3. M.J. Reginato, S.T. Bailey, S.L. Krakow, C. Minami, S. Ishii, and H. Tanaka A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties J. Biol. Chem. 273 1998 32679 32684
4. L.A. Sorbera, J. Castaner, M. del Fresno, and J. Silvestre Netoglitazone. Antidiabetic PPARα/PPARγ agonist Drugs Future 27 2002 132 139
5. L. Pickavance, P.S. Widdowson, P. King, S. Ishii, H. Tanaka, and G. Williams The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment Br. J. Pharmacol. 125 1998 767 770
6. R. Upton, P.S. Widdowson, S. Ishii, H. Tanaka, and G. Williams Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555 Br. J. Pharmacol. 125 1998 1708 1714
7. Y. Jiang, B.N. Jahagirdar, R.L. Reinhardt, R.E. Schwartz, C.D. Keene, and X.R. Ortiz-Gonzalez Pluripotency of mesenchymal stem cells derived from adult marrow Nature 418 2002 41 49
8. P. Bianco, M. Riminucci, S. Gronthos, and P.G. Robey Bone marrow stromal stem cells: nature, biology, and potential applications Stem Cells 19 2001 180 192
9. J.N. Beresford, J.H. Bennett, C. Devlin, P.S. Leboy, and M.E. Owen Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures J. Cell Sci. 102 1992 341 351
10. E.J. Moerman, K. Teng, D.A. Lipschitz, and B. Lecka-Czernik Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways Aging Cell 3 2004 379 389
11. B. Lecka-Czernik, I. Gubrij, E.A. Moerman, O. Kajkenova, D.A. Lipschitz, and S.C. Manolagas Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2 J. Cell. Biochem. 74 1999 357 371
12. S.O. Rzonca, L.J. Suva, D. Gaddy, D.C. Montague, and B. Lecka-Czernik Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 145 2004 401 406
13. V. Sottile, K. Seuwen, and M. Kneissel Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone) Calcif. Tissue Int. 75 2004 329 337
14. M.A. Soroceanu, D. Miao, X.Y. Bai, H. Su, D. Goltzman, and A.C. Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol. 183 2004 203 216
15. T.A. Cock, J. Back, F. Elefteriou, G. Karsenty, P. Kastner, and S. Chan Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen EMBO Rep. 5 2004 1007 1012
16. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 2004 1226 1235
17. T. Akune, S. Ohba, S. Kamekura, M. Yamaguchi, U.I. Chung, and N. Kubota PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors J. Clin. Invest. 113 2004 846 855
18. S. Ogawa, T. Urano, T. Hosoi, M. Miyao, S. Hoshino, and M. Fujita Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts Biochem. Biophys. Res. Commun. 260 1999 122 126
19. B. Lecka-Czernik, E.J. Moerman, D.F. Grant, J.M. Lehmann, S.C. Manolagas, and R.L. Jilka Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation Endocrinology 143 2002 2376 2384
20. T.M. Willson, M.H. Lambert, and S.A. Kliewer Peroxisome proliferator-activated receptor gamma and metabolic disease Annu. Rev. Biochem. 70 2001 341 367
21. Z.S. Xiao, R. Thomas, T.K. Hinson, and L.D. Quarles Genomic structure and isoform expression of the mouse, rat and human Cbfa1/Osf2 transcription factor Gene 214 1998 187 197
22. B. Lecka-Czernik, E.J. Moerman, R.J. Shmookler Reis, and D.A. Lipschitz Cellular and molecular biomarkers indicate precocious in vitro senescence in fibroblasts from SAMP6 mice. Evidence supporting a murine model of premature senescence and osteopenia J. Gerontol. A Biol. Sci. Med. Sci. 52 1997 B331 B336
23. P. Ducy, R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation Cell 89 1997 747 754
24. G.L. Wolff, D.W. Roberts, and K.G. Mountjoy Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome Physiol. Genomics 1 1999 151 163
25. J.D. Fluckey, E.E. Dupont-Versteegden, D.C. Montague, M. Knox, P. Tesch, and C.A. Peterson A rat resistance exercise regimen attenuates losses of musculoskeletal mass during hindlimb suspension Acta Physiol. Scand. 176 2002 293 300
26. T. Hildebrand, and P. Ruegsegger Quantification of bone microarchitecture with the structure model index Comput. Methods Biomech. Biomed. Eng. 1 1997 15 23
27. D. Amblard, M.H. Lafage-Proust, A. Laib, T. Thomas, P. Ruegsegger, and C. Alexandre Tail suspension induces bone loss in skeletally mature mice in the C57BL/6J strain but not in the C3H/HeJ strain J. Bone Miner. Res. 18 2003 561 569
28. M.S. Bendre, D. Gaddy-Kurten, T. Mon-Foote, N.S. Akel, R.A. Skinner, and R.W. Nicholas Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo Cancer Res. 62 2002 5571 5579
29. M. Balcerzak, E. Hamade, L. Zhang, S. Pikula, G. Azzar, and J. Radisson The roles of annexins and alkaline phosphatase in mineralization process Acta Biochim. Pol. 50 2003 1019 1038
30. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 1995 12953 12956
31. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Wilson, W. Palinski, and C.K. Glass Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106 2000 523 531
32. J.P. Frias, J.G. Yu, Y.T. Kruszynska, and J.M. Olefsky Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects Diabetes Care 23 2000 64 69
33. M. Diamant, and R.J. Heine Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence Drugs 63 2003 1373 1405
34. P.S. Gillies, and C.J. Dunn Pioglitazone Drugs 60 2000 333 343 (discussion 344-5)
35. C.N. Bennett, K.A. Longo, W.S. Wright, L.J. Suva, T.F. Lane, and K.D. Hankenson Regulation of osteoblastogenesis and bone mass by Wnt10b Proc. Natl. Acad. Sci. U. S. A. 102 2005 3324 3329
36. M.E. Nuttall, and J.M. Gimble Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27 2000 177 184
37. J.M. Gimble, and M.E. Nuttall Bone and fat: old questions, new insights Endocrine 23 2004 183 188
38. L. Tornvig, L.I. Mosekilde, J. Justesen, E. Falk, and M. Kassem Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice Calcif. Tissue Int. 69 2001 46 50
39. M. Kveiborg, G. Sabatakos, R. Chiusaroli, M. Wu, W.M. Philbrick, and W.C. Horne DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms Mol. Cell. Biol. 24 2004 2820 2830
40. A.F. Schilling, T. Schinke, C. Munch, M. Gebauer, A. Niemeier, and M. Priemel Increased bone formation in mice lacking apolipoprotein E J. Bone Miner. Res. 20 2005 274 282
41. A.V. Schwartz, T.A. Hillier, D.E. Sellmeyer, H.E. Resnick, E. Gregg, and K.E. Ensrud Older women with diabetes have a higher risk of falls: a prospective study Diabetes Care 25 2002 1749 1754
42. A.V. Schwartz, D.E. Sellmeyer, E.S. Strotmeyer, F.A. Tylavsky, K.R. Feingold, and H.E. Resnick Diabetes and bone loss at the hip in older black and white adults J. Bone Miner. Res. 20 2005 596 603